Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Int J Cancer
    January 2026
  1. FURLANO K, Keshavarzian T, Biernath N, Fendler A, et al
    Epigenomics-guided precision oncology: Chromatin variants in prostate tumor evolution.
    Int J Cancer. 2026;158:314-332.
    >> Share

  2. SABBAGHIAN A, Lin H, Lim YP
    WBP2 and its network of transcription coregulators in an expanding repertoire of human cancers.
    Int J Cancer. 2026;158:218-231.
    >> Share

    December 2025
  3. TANG Y, Han Z, Yi X, Li J, et al
    Survival improvements and disparities in metastatic prostate adenocarcinoma, clear cell renal cell carcinoma, and urothelial carcinoma of bladder.
    Int J Cancer. 2025;157:2485-2494.
    >> Share


  4. RETRACTION: Hsp27 Regulates EGF/beta-Catenin Mediated Epithelial to Mesenchymal Transition in Prostate Cancer.
    Int J Cancer. 2025 Dec 3. doi: 10.1002/ijc.70279.
    >> Share

    November 2025
  5. JENSBY EF, Klingenberg S, Fredsoe J, Fonfara KE, et al
    Training and validation of a novel 14-gene expression signature associated with prostate cancer metastasis and postoperative recurrence.
    Int J Cancer. 2025 Nov 17. doi: 10.1002/ijc.70247.
    >> Share

    October 2025
  6. VLAMING M, Bleiker EMA, Schijven G, Kiemeney LALM, et al
    Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway.
    Int J Cancer. 2025 Oct 13. doi: 10.1002/ijc.70194.
    >> Share

    September 2025
  7. SANTIAGO LR, Ladoukakis E, Scibior-Bentkowska D, Nedjai B, et al
    Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer.
    Int J Cancer. 2025 Sep 16. doi: 10.1002/ijc.70163.
    >> Share

  8. CHOPRA R, Li H, Xie W, Lam DHT, et al
    Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.
    Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70149.
    >> Share

  9. LIN E, Garmo H, Beckmann K, Bratt O, et al
    Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70133.
    >> Share

  10. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
    Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
    Int J Cancer. 2025;157:1006-1019.
    >> Share

    August 2025
  11. HAN Y, Li C, Sun J, Wu G, et al
    Comments on "CTHRC1 promotes bone metastasis in prostate cancer".
    Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70081.
    >> Share

    July 2025
  12. OKWOR UE, Raitanen J, Talala K, Tammela TLJ, et al
    Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.
    Int J Cancer. 2025 Jul 17. doi: 10.1002/ijc.70026.
    >> Share

  13. MUCHADEYI MT, Hao S, Hernandez-Villafuerte K, Khan SA, et al
    Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.
    Int J Cancer. 2025 Jul 16. doi: 10.1002/ijc.35513.
    >> Share

    June 2025
  14. STITZ R, Stoiber F, Silye R, Rebhan E, et al
    Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70019.
    >> Share

  15. SAWADA Y, Kikugawa T, Onishi T, Arai O, et al
    CTHRC1 promotes bone metastasis in prostate cancer.
    Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70012.
    >> Share

    December 2024
  16. SIECH C, de Angelis M, Jannello LMI, Di Bello F, et al
    Life expectancy in rare histological prostate cancer subtypes.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35323.
    >> Share

  17. MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al
    Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
    Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279.
    >> Share

    October 2024
  18. GRENVILLE ZS, Noor U, Rinaldi S, Gunter MJ, et al
    Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35208.
    >> Share

    September 2024
  19. MOGHUL M, Tran A, Croft F, Kinsella N, et al
    The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
    Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169.
    >> Share

    July 2024
  20. BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al
    Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Int J Cancer. 2024;155:314-323.
    >> Share

    June 2024
  21. HUANG CY, Huang CP, Huang YY, Huang SK, et al
    Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
    Int J Cancer. 2024 Jun 26. doi: 10.1002/ijc.35040.
    >> Share

  22. SEE AW, Conway P, Frydenberg M, Haxhimolla H, et al
    Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35052.
    >> Share

    April 2024
  23. LUO Y, Yu J, Lin Z, Wang X, et al
    Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967.
    >> Share

  24. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    >> Share

    March 2024
  25. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    >> Share

  26. LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al
    Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
    Int J Cancer. 2024;154:926-939.
    >> Share

  27. ZHANG Y, Stopsack KH, Song M, Mucci LA, et al
    Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34898.
    >> Share

    February 2024
  28. CARUANA M, Gulati R, Etzioni R, Barratt A, et al
    Benefits and harms of prostate specific antigen testing according to Australian guidelines.
    Int J Cancer. 2024;154:648-658.
    >> Share

    January 2024
  29. SCHUURMAN MS, Lemmens VEPP, Portielje JEA, van der Aa MA, et al
    The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019.
    Int J Cancer. 2024;154:261-272.
    >> Share

  30. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    >> Share

    November 2023
  31. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    >> Share

  32. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    >> Share

  33. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    >> Share

    October 2023
  34. ALMURADOVA E, Seyyar M, Arak H, Tamer F, et al
    The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016